A SiftingSignal publication/ Edited by Simon Mathews, MD

The week in GI, filtered to what is worth knowing.

Every week, 100+ papers from 25+ top GI and medical journals, transparently scored and physician-vetted. The signal, not the noise.

This week, in numbers

Issue №11 · week of Sep 13, 2026See the trends →
Top journals this week: Nat Rev Gastro Hep / Lancet GH / Gastroenterology / Gut
Selectivity
10.3%
15 in the issue of 145 screened
in the issue 15in depth 30held 10filtered out 90
89.7% of what published this week did not make the issue. That filter is the product. A further 30 cleared the bar and are carried in one line each, in full on the subspecialty pages.
How this week moves the standard
Changes practice 0
No paper this week forces an outright change to the standard. That is the usual, honest result.
Each paper is matched to the guideline that governs its question, then placed by how it moves it. 14 of the 15 cards in the issue are matched to a standard, and each of those quotes it with its source and review date. Click a segment to filter the issue.
The signal map
567389retrospectiveguideline →Clinical utilityEvidence strength
Each dot is a paper: evidence strength across, clinical utility up (what you can do with it, what rides on it, how many patients, how new), area = the journal's impact factor, colour = subspecialty. A dark ring marks a paper that refines or changes its standard of care. The vertical scale spans this week's cards and its numbers are the real scores out of 100. Click a dot to open its card.

What to know this week

the top-scored · the 5-minute version

top-down anti-TNF from diagnosis cuts 5-year surgery to 3% versus 13% with step-up, resmetirom and semaglutide now approved for MASH F2-F3, and Peg-IFN to nucleos(t)ides: 38% HBsAg loss if baseline <100 IU/mL, 47.5% drop to <1000 if baseline ≥1000 at 48 weeks.

The 15 in the issue this week, ranked by signal score. Each anchored to the relevant standard of care. All in full below; 30 more, read and scored the same way, in one line each at the foot of the issue.

Your subspecialty, the takeaways
IBD9Hepatology16Esophagus/Reflux3Pancreas/Biliary3Endoscopy10Motility1Colorectal1Nutrition2
Type

This week to know

the 5 strongest this week · each scored 0 to 100 on what it lets you do, who it touches, the stakes, and how well the evidence backs it
IBD rct · n=389 · Sep 10, 2026 · Lancet GH · IF 39.1

Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial.

Practice-changingCrohn's diseasebiologicsanti-TNF
Clinical takeawayIn newly diagnosed Crohn's disease, initiate combined TNF inhibitor plus immunomodulator therapy at diagnosis rather than escalating gradually. The top-down approach reduces 5-year surgery risk by approximately 80%. This durable benefit persists even though most step-up patients eventually receive biologics by year 5, showing an early critical window for intervention.
What it foundStep-up therapy increased 5-year abdominal surgery hazard 5.23-fold compared to top-down anti-TNF plus immunomodulator from diagnosis (95% CI 1.99-13.76, p=0.0008); absolute surgery rates were 13% step-up versus 3% top-down.
ContextThis literature reports that the PROFILE trial's 5-year follow-up demonstrates sustained clinical benefit from top-down anti-TNF therapy initiated at diagnosis in newly diagnosed Crohn's disease compared to conventional step-up treatment strategies.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakeWhether to initiate anti-TNF therapy with immunomodulator from diagnosis versus step-up conventional therapy in newly diagnosed Crohn's disease

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Noor NM … PROFILE Study Group · Lancet Gastroenterology & Hepatology · IF 39.1 · PubMed ↗Permalink
Hepatology guideline · Sep 11, 2026 · Gut · IF 24.6

International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.

New therapyMASLDguideline
Clinical takeawayPracticing GIs can now offer pharmacological treatment for MASH F2-F3 using resmetirom or semaglutide. This expert panel provides decision support for drug selection by patient phenotype, initiation protocols, on-treatment monitoring, response assessment, dose adjustment, and criteria for combining or switching agents.
What it foundResmetirom (thyroid hormone receptor-beta agonist) and semaglutide (GLP-1 RA) are the first FDA-approved pharmacological treatments for MASH F2-F3, marking the first therapy option for a previously untreated condition; expert panel consolidates phase III trial data and clinical guidance for their use.
ContextMASH F2-F3 previously had no pharmacological options. Resmetirom and semaglutide are the first FDA-approved agents for this indication, acting through complementary mechanisms. This expert consolidation replaces a prior era of supportive care alone with a structured clinical decision framework.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)

Decision at stakechoosing between resmetirom and semaglutide for MASH with F2-F3 fibrosis and assessing on-treatment response

… Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). … On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.

EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798) · reviewed 2026-10-11 ↗
Mironova M … Loomba R · Gut · IF 24.6 · PubMed ↗Permalink
Hepatology meta analysis · n=581 · Sep 7, 2026 · Gut · IF 24.6

HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).

New evidenceviral hepatitismeta-analysis
Clinical takeawayIn HBV patients on nucleos(t)ides pursuing HBsAg clearance or cure strategies, peg-IFN add-on success depends on baseline level. Patients with baseline <100 had ~38% HBsAg loss rate; baseline <1000 (combined <100 and 100-1000 strata) had ~18%. For higher-baseline patients (≥1000), use peg-IFN as lead-in to achieve intermediate reductions (47.5% reach HBsAg <1000 at 48 weeks), supporting sequential cure regimens with novel antivirals.
What it foundPeg-IFN added to nucleos(t)ide analogues achieved HBsAg loss in 38% of patients with baseline <100 IU/mL and 18% with baseline <1000 IU/mL. For patients with baseline ≥1000 IU/mL, intermediate HBsAg reductions occurred more frequently: 48 weeks of peg-IFN achieved HBsAg <1000 in 47.5% and <100 in 16.3%. Overall HBsAg loss occurred in 50/581 (8.6%).
ContextIndividual participant data meta-analysis of 8 prospective trials (581 patients; 44% HBeAg-positive at baseline) providing baseline-stratified HBsAg loss rates and intermediate reduction milestones-useful data for patient selection in chronic hepatitis B.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026

Decision at stakeWhether to add peg-IFN to nucleos(t)ide analogues for HBsAg reduction or loss

… (5) DISCONTINUATION, in adults with CHB who are HBeAg-negative, without cirrhosis, with sustained undetectable HBV DNA on nucleos(t)ide analogue therapy, AASLD SUGGESTS NOT withdrawing NA therapy until HBsAg loss (CONDITIONAL, VERY LOW certainty). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

The 2026 AASLD/IDSA guideline addresses six PICO questions only; it states explicitly that all other 2018 AASLD recommendations for CHB management remain applicable, and that screening/diagnosis were out of scope. Baseline evaluation and the standard treatment indications (cirrhosis with detectable HBV DNA; HBeAg-positive immune-active with ALT >2x ULN and HBV DNA >20,000 IU/mL; HBeAg-negative immune-active with ALT >2x ULN and HBV DNA >2,000 IU/mL; prophylaxis for reactivation risk during immunosuppression) derive from the 2018 document, not this update, which lists 'treatment of HBeAg-positive and -negative immune active CHB with ALT >2x ULN', treatment of children, treatment of cirrhosis, low-level viremia, virologic breakthrough, and special populations (transplant, acute HBV, HCV/HDV/HIV coinfection) as topics 'well covered in previous AASLD 2018 Guidance and for which recommendations have not changed'. Preferred agents remain entecavir, TDF, or TAF. THE SIX 2026 RECOMMENDATIONS: (1) PMTCT, for pregnant persons with HBV DNA >200,000 IU/mL at any time point during pregnancy, regardless of HBeAg status, AASLD RECOMMENDS initiating TDF or TAF at gestational week 28 (STRONG recommendation, MODERATE certainty, the only strong recommendation in the guideline); TDF has a more extensive safety record in pregnancy than TAF. Implementation qualifiers: initiate immediately if care is first sought after week 28; initiate at week 16 if infant HBIG will be unavailable (with subsequent infant vaccination); consider earlier initiation when amniocentesis is anticipated (transmission risk is increased with HBV DNA >2,000,000 IU/mL) or when preterm labor risk is high; continue TDF/TAF if already on it, switch entecavir or other agents to TDF/TAF; if treatment was solely for perinatal prophylaxis it may be discontinued at delivery, with HBV DNA and ALT monitored every 1-3 months for up to 6 months for withdrawal flare and treatment reinitiated if ALT >=5x ULN; use TDF or TAF in breastfeeding persons requiring treatment. (2) HORIZONTAL TRANSMISSION, for HBsAg-positive viremic persons not meeting disease-specific treatment indications who are in high-risk scenarios for transmission to others, AASLD SUGGESTS a shared decision-making approach regarding antiviral treatment (CONDITIONAL, VERY LOW certainty). Qualifiers the guideline stresses: the decision weighs exposure risk and the vaccine/immunity status of contacts, favoring treatment if contacts are unvaccinated, vaccine-nonresponsive, immunocompromised, or of unknown vaccine status; persons requesting treatment for prevention may be prescribed it since risks may not be disclosed; explicitly, people with CHB must NOT be restricted in daily activities, contact sports, school, or professional training and must NOT be required to take antivirals because of transmission risk in those settings; routine contact, shared meals, and hugging are not transmission routes (avoid sharing toothbrushes/razors); most healthcare workers with CHB are NOT high-risk, but those performing SHEA Category III exposure-prone procedures may require antivirals (SHEA target HBV DNA <1000 IU/mL); neither CDC nor SHEA requires disclosure to patients or staff; anti-stigma framing is part of the recommendation. (3) IMMUNE-TOLERANT PHASE, defined as HBeAg-positive, HBV DNA >10^7 IU/mL, and normal ALT; AASLD SUGGESTS antiviral therapy for those over age 40 years, OR with significant liver inflammation (grade >=2) or fibrosis (>=F2) on biopsy or noninvasive tests (CONDITIONAL, VERY LOW certainty). For persons under age 40 who are interested in starting treatment earlier, AASLD suggests shared decision-making weighing risk factors and the benefits and risks of treatment. Accurate phase identification requires persistently normal ALT on >=2 measurements >=6 months apart, using ULN 35 U/L (males) and 25 U/L (females). (4) INDETERMINATE ('grey zone') PHASE, the HBeAg-negative indeterminate phase is defined as HBsAg-positive, HBeAg-negative persons whose ALT and/or HBV DNA fall outside the thresholds for HBeAg-negative immune-active CHB (ALT >2x ULN and HBV DNA >2,000 IU/mL) and outside those for inactive CHB (HBV DNA <2,000 IU/mL with normal ALT), comprising predominantly two subgroups, (I) normal (<ULN) or mildly elevated (<2x ULN) ALT with HBV DNA >=2,000 IU/mL, or (II) elevated ALT (>ULN) with HBV DNA <2,000 IU/mL, with ALT interpreted against ULN 35 U/L (males) and 25 U/L (females) and phase assigned on >=2 ALT and HBV DNA measurements over a 6-12 month period; in adults who are HBsAg-positive, HBeAg-negative, without cirrhosis and in the indeterminate phase so defined, AASLD SUGGESTS antiviral therapy using a shared decision-making approach assessing risks and benefits, and re-evaluating that decision at each follow-up visit if treatment has not been initiated (CONDITIONAL, VERY LOW certainty). Decision-relevant factors include fibrosis stage, age, and sex, e.g. age >40, male sex, and low-normal platelets (<180 k/mm3) favor treatment. (5) DISCONTINUATION, in adults with CHB who are HBeAg-negative, without cirrhosis, with sustained undetectable HBV DNA on nucleos(t)ide analogue therapy, AASLD SUGGESTS NOT withdrawing NA therapy until HBsAg loss (CONDITIONAL, VERY LOW certainty). If a patient nonetheless has a strong desire to stop, shared decision-making applies and ALL of the following must be met: no history of advanced fibrosis/cirrhosis, hepatic decompensation (variceal bleed, ascites, encephalopathy, hepatorenal syndrome), HCC, or extrahepatic HBV complications; if HBeAg-positive at treatment start, HBeAg seroconversion to anti-HBe-positive for >=1 year with undetectable HBV DNA >=2 years; if HBeAg-negative at start, undetectable HBV DNA >=2 years; no HIV or HDV coinfection; quantitative HBsAg <100 IU/mL; and willingness to adhere to frequent monitoring. After stopping, monitor ALT and HBV DNA every 1-3 months for 6 months, then every 3 months for 6-12 months, then every 3-6 months. Restart antivirals IMMEDIATELY if HBV DNA >=10,000 IU/mL (4 log IU/mL) at any time regardless of ALT, OR ALT >=5x ULN regardless of HBV DNA, OR total bilirubin >2.5 mg/dL. (6) HCC SURVEILLANCE (all CONDITIONAL, VERY LOW certainty; modality/interval per AASLD 2023 HCC Practice Guidance), Rec 6: after HBsAg loss, continue surveillance in those with cirrhosis, family history of HCC, men who lost HBsAg after age 40, and women who lost HBsAg after age 50. Rec 7: in HBV-HDV coinfection, surveil adults independent of cirrhosis status; in children, individualize because HCC risk in that population is unknown. Rec 8: in HBV-HIV coinfection, surveil men >=18 years and women >=40 years. Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria. Where a person has more than one coinfection, the surveillance recommendation should follow the coinfection carrying the highest associated risk. The guideline notes that most of its recommendations rest on low or very low certainty evidence and that shared decision-making, not uniform policy, is the intended mode of application.

American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026 · reviewed 2026-07-23 ↗
Dongelmans EJ … Sonneveld MJ · Gut · IF 24.6 · PubMed ↗Permalink
Hepatology prospective cohort · n=13,627 · Sep 8, 2026 · Clin Gastro Hep · IF 16.2

Personalised prediction of the individual risk of liver-related events in MASLD using the dynamics of non-invasive tests.

New evidenceMASLDcirrhosishepatocellular carcinomaartificial intelligence
Clinical takeawayThe JLCM improves discrimination for cirrhosis decompensation and HCC risk within the VCTE-Prognosis cohort compared to static LSM or FIB-4 alone. Prospective external validation in independent MASLD populations and deployment of a validated risk calculator are required before recommending clinical use for surveillance intensity or treatment decisions.
What it foundJoint latent class model incorporating LSM trajectory, FIB-4, sex, age, and platelets identified 61-80% of patients who developed cirrhosis decompensation or HCC across follow-up visits, compared to 39-56% with LSM alone and 32-60% with FIB-4, achieving AUROC 92.2% at 5-year follow-up.
ContextThis literature reports that personalised risk prediction for liver-related events in MASLD can be derived from longitudinal trends in non-invasive fibrosis markers, addressing the clinical challenge of interpreting dynamic test changes.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)

Decision at stakehow to use non-invasive fibrosis tests (LSM, FIB-4) to predict which MASLD patients will develop cirrhosis decompensation or hepatocellular carcinoma

… A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. … Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. … In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.

EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798) · reviewed 2026-10-11 ↗
Moreau C … Boursier J · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Esophagus/Reflux retrospective · n=230 · Sep 8, 2026 · J Gastro Hep · IF 3.5

Clinical Spectrum of Esophageal Motility Disorders in Nonobstructive Dysphagia: A Multicenter, Multiethnic Study.

Diagnosticesophageal motilitydysphagiaachalasiabiomarker
Clinical takeawayIn patients with nonobstructive dysphagia, recognize weight loss, nausea, and absence of dyspepsia as clues to achalasia. Use RDC-IRP at approximately 18 mmHg during HRM to differentiate achalasia from EGJOO. This threshold was validated in an Asian population; generalizability to other demographics may require confirmation.
What it foundAmong 230 Asian dysphagia patients, achalasia (23.9%) was predicted by weight loss (adjusted OR 2.99), nausea/vomiting (OR 3.35), and absence of dyspepsia (OR 0.09). RDC-IRP at 18 mmHg threshold differentiated achalasia from non-achalasia with 90% sensitivity, 76.9% specificity, and AUC 0.894.
ContextAchalasia diagnosis relies on HRM and Chicago Classification criteria, which are standard. This study validates the RDC-IRP (rapid drink challenge integrated relaxation pressure) threshold for differentiation from EGJOO in a multiethnic Asian population, providing an actionable diagnostic refinement.
Refinessuggested applicable standard· International Working Group for Disorders of Gastrointestinal Motility and Function (Chicago Classification Working Group); Yadlapati R, Kahrilas PJ, Fox MR, et al. "Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©." Neurogastroenterology & Motility. 2021;33(1):e14058

Decision at stakeUse rapid drink challenge-integrated relaxation pressure to discriminate achalasia from other esophageal motility disorders when baseline IRP values are borderline or overlap between diagnoses

Diagnose non-achalasia esophageal motility disorders on high-resolution manometry performed with the full CCv4.0 protocol, and treat the manometric pattern as a disorder only when it is accompanied by clinically relevant symptoms. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose non-achalasia esophageal motility disorders on high-resolution manometry performed with the full CCv4.0 protocol, and treat the manometric pattern as a disorder only when it is accompanied by clinically relevant symptoms. The protocol requires both positions: supine (60-second adaptation, 30-second landmark/baseline, ten 5 mL wet swallows, one multiple rapid swallow of five 2 mL swallows at 2-3 second intervals) and upright at >=80 degrees (five 5 mL wet swallows plus a 200 mL rapid drink challenge); solid swallows, a solid test meal, or pharmacologic provocation (amyl nitrite, cholecystokinin) are added when standard swallows do not explain the symptom. IRP thresholds are manufacturer- and position-specific (for the Medtronic system, abnormal median IRP is >=15 mmHg supine and >=12 mmHg upright). CCv4.0 grades diagnoses as conclusive or inconclusive: distal esophageal spasm requires a normal median IRP plus >=20% premature contractions (distal latency <4.5 s with DCI >=450 mmHg*s*cm) AND clinically relevant dysphagia or non-cardiac chest pain; hypercontractile esophagus requires a normal median IRP plus >=20% hypercontractile supine swallows (DCI >8,000 mmHg*s*cm) AND clinically relevant dysphagia or non-cardiac chest pain, with mechanical obstruction excluded. Ineffective esophageal motility requires a normal IRP in both positions plus >70% ineffective swallows or >=50% failed peristalsis, where an ineffective swallow is weak (DCI 100-450), failed (DCI <100), or fragmented; 50-70% ineffective swallows is inconclusive and requires supportive testing. Absent contractility requires a normal median IRP in both supine and upright positions with 100% failed peristalsis, and because achalasia can present this way, provocative testing and adjunctive investigation are needed when there is any clinical suspicion of achalasia. Manometric EGJ outflow obstruction is never conclusive on manometry alone: it requires an elevated median IRP in BOTH the primary and secondary position plus >=20% of swallows with elevated intrabolus pressure, with peristalsis preserved; a conclusive, clinically relevant diagnosis additionally requires compatible symptoms (dysphagia or non-cardiac chest pain) AND at least one supportive investigation showing obstruction (timed barium esophagram with tablet and/or functional lumen imaging probe). An isolated elevated supine IRP, an isolated elevated upright IRP, or isolated elevated intrabolus pressure alone are each inconclusive and do not establish EGJOO. CCv4.0 is a diagnostic classification and does not issue treatment recommendations; therapy for these entities is not traceable to this document.

International Working Group for Disorders of Gastrointestinal Motility and Function (Chicago Classification Working Group); Yadlapati R, Kahrilas PJ, Fox MR, et al. "Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©." Neurogastroenterology & Motility. 2021;33(1):e14058 · reviewed 2026-07-19 ↗
Lim JX … Chuah KH · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink

The read

the next 10, in full

IBD· 3

IBD prospective cohort · Sep 11, 2026 · J Clin Gastro · IF 2.9

Pharmacokinetic Predictor of Infection in Patients With Inflammatory Bowel Disease Treated With Intravenous and Subcutaneous Infliximab.

New evidencetherapeutic drug monitoringanti-TNFbiomarkerCrohn's disease
Clinical takeawayDuring IFX therapeutic drug monitoring, AUC predicted infection risk more strongly than Ctrough alone. Consider AUC in infection-risk assessment for dose decisions in IBD patients on IFX; however, this is observational evidence for an association, and whether AUC-guided dose adjustment will reduce infections has not been tested in a trial.
What it foundCumulative infliximab exposure over 8 weeks (AUC, OR 1.03 per 100 mg·d/L, 95% CI 1.01-1.05) predicted infection in a prospective cohort of 2451 treatment episodes, whereas trough concentration (Ctrough) did not.
ContextCtrough-based IFX monitoring is standard practice for optimizing drug levels and efficacy. This prospective cohort suggests cumulative exposure (AUC) may be a superior predictor of infection risk, potentially refining patient risk stratification; however, this challenges the current paradigm without proving that dose adjustment based on AUC will prevent infections.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakepharmacokinetic monitoring strategy for infliximab to predict and mitigate infection risk

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Kim JE … Kim YH · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
IBD prospective cohort · n=606 · Sep 8, 2026 · Clin Gastro Hep · IF 16.2

Influence of socioeconomic development on incidence and disease phenotype in inflammatory bowel disease: a population-based incident study across 16 regions.

EpidemiologyCrohn's diseaseulcerative colitisepidemiologyperianal disease
Clinical takeawayIn newly industrializing regions experiencing ongoing urbanization and economic development, expect higher IBD incidence, particularly CD, and heighten diagnostic suspicion accordingly. In more economically developed settings (higher Human Development Index), perianal CD is more common and should be specifically sought during CD evaluation. Disease activity and severity at presentation do not differ by development level, so initial treatment intensity should not be modified based on regional development.
What it foundUrbanization (per 10% increase in urban population) increased IBD incidence (IRR 1.68 overall; CD 1.73, UC 1.62). CD incidence associated with national HDI (IRR 4.05) and SDI (IRR 2.96). Both national and subnational HDI associated with perianal CD (aOR 2.61 and 2.40 respectively). Disease activity and treatment patterns unchanged by development indices.
ContextPopulation-based surveillance across 16 newly industrialized regions documents variation in IBD incidence and clinical phenotype correlating with socioeconomic development indices, though mechanistic drivers remain incompletely characterized.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakeRecognition of perianal CD phenotype during initial workup in high-development regions

… DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes MILD-TO-MODERATE.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Mak JWY … GIVES-21 Consortium · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
IBD prospective cohort · n=391 · Sep 10, 2026 · Aliment Pharm Ther · IF 6.7

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

New evidenceCrohn's diseaseJAK inhibitors
Clinical takeawayIn AT-experienced, moderate-to-severe CD patients, upadacitinib is an effective next-step option with particular benefit for those with active extraintestinal manifestations. Assess for remission by week 12 (51.2% achieved); higher baseline HBI predicts lower remission likelihood. Safety profile is favourable in this real-world cohort, though evidence is observational rather than randomised.
What it foundIn AT-experienced CD, upadacitinib achieved 54.7% remission (HBI ≤ 4) at week 24, 65.7% complete resolution of active extraintestinal manifestations by week 24, 11.3% discontinuation by week 24 (3.1% from adverse events), and no major cardiovascular, thromboembolic, or malignancy events.
ContextUpadacitinib was approved for moderate-to-severe CD, but real-world prospective data in heavily pretreated populations was limited. This multicentre observational study confirms sustained efficacy through 6 months and provides reassurance on safety specifically in AT-experienced patients-those for whom earlier advanced therapies have failed-addressing a key knowledge gap for practising clinicians.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakeUse upadacitinib for induction and maintenance in patients previously exposed to anti-TNF agents

… MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. … The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Barberio B … Savarino EV · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink

Hepatology· 4

Hepatology prospective cohort · n=938 · Sep 10, 2026 · Clin Gastro Hep · IF 16.2

Assessing Strategies to Mitigate the Effect of Age When Using FIB-4 Index to Screen for MASLD-Related Liver Fibrosis.

New evidenceMASLDbiomarkercirrhosis
Clinical takeawayIn MASLD patients at age extremes (<35 or ≥65 years), use FIB-3 (AST/ALT/platelet-based, age-omitted) instead of standard FIB-4 for fibrosis screening. It maintains equivalent diagnostic accuracy without the age-related bias that causes FIB-4 to underestimate risk in younger patients and overestimate in older patients, pending prospective confirmation for guideline adoption.
What it foundFIB-3 (age-removed from FIB-4; exact formula in source paper) maintained diagnostic accuracy of standard FIB-4 for detection of ≥F2 and ≥F3 MASLD fibrosis (AUROCs 0.76-0.78 vs MRE, 0.77-0.81 vs biopsy, all five strategies similar), while demonstrating improved sensitivity-specificity balance specifically at age extremes (<35 and ≥65 years).
ContextFIB-4 is guideline-recommended for MASLD screening but has known limitations at age extremes: the formula overestimates fibrosis in older patients and underestimates it in younger patients because age is a direct component. This study validates that removing age (FIB-3) maintains equivalent diagnostic accuracy while eliminating this bias, suggesting age-independent calculation could improve screening across age strata.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Nammi J … Bril F · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatology retrospective · n=93 · Sep 8, 2026 · Aliment Pharm Ther · IF 6.7

Pharmacokinetic and Pharmacodynamic Variability Predict Late Events After Paediatric Liver Transplantation: Derivation and External Validation of a Landmark Risk Score.

New evidenceliver transplantpediatricbiomarker
Clinical takeawayAt 12 months post-pediatric liver transplant in recipients without major early complications (6-12 months post-transplant), calculate tacrolimus, aspartate aminotransferase, and total bilirubin variability from prior 6 months of measurements; score of 2-3 identifies patients at 4-9x higher risk for late complications or graft loss, warranting closer surveillance. Population predominantly biliary atresia.
What it foundA variability-based risk score (tacrolimus >25%, aspartate aminotransferase >50%, total bilirubin >50%) derived and externally validated at 12 months post-transplant, where score 2-3 identified higher-risk patients with hazard ratio 4.48 (95% CI 1.79-11.17) in derivation and 8.90 (95% CI 2.66-29.81) in validation cohorts.
ContextChallenges the sufficiency of cross-sectional tacrolimus concentrations and static liver biochemistry in post-transplant monitoring. Demonstrates that longitudinal instability and variability are better predictors of adverse long-term outcomes. Derived and externally validated in pediatric recipients, predominantly with biliary atresia, without early major complications.
Refinessuggested applicable standard· AASLD/AST, 'AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation' (Dove L et al., Hepatology 2026;83(6):1609-1645). DOI 10.1097/HEP.0000000000001644, PMID 41405234.

Decision at stakeidentify which post-transplant liver recipients require intensive long-term surveillance

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Refer patients with decompensated cirrhosis (including those with MELD-Na <15 or MELD 3.0 <15 if they have clinically significant portal hypertension, recurrent ascites, hepatic encephalopathy, or variceal bleeding), acute liver failure meeting King's College Criteria/UNOS Status 1A, or HCC within Milan/UCSF criteria for comprehensive multidisciplinary liver transplant evaluation, with MELD 3.0 driving UNOS waitlist allocation and MELD exception scoring for HCC/HPS/FAP. Optimize modifiable risk factors before listing (alcohol abstinence, HCV DAA treatment, vaccinations, DM/obesity/OSA and dental clearance) and use bridging/downstaging locoregional therapy for HCC while awaiting transplant. After transplant, maintain lifelong immunosuppression with tacrolimus plus mycophenolate ± tapered steroids alongside infection prophylaxis and recurrent-disease surveillance.

AASLD/AST, 'AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation' (Dove L et al., Hepatology 2026;83(6):1609-1645). DOI 10.1097/HEP.0000000000001644, PMID 41405234. · reviewed 2026-07-21 ↗
Tang H … Zhang M · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
Hepatology retrospective · n=150 · Sep 9, 2026 · J Gastro Hep · IF 3.5

The Impact of HCC Surveillance on Tumor Features and Receipt of Curative Therapy: A Focus on Chronic Hepatitis B and MASLD.

New evidencehepatocellular carcinomaMASLDviral hepatitishealth services
Clinical takeawayEnsure HCC surveillance in cirrhotic patients, HBV carriers, and MASLD patients. Surveillance-diagnosed patients had 17.8-fold higher odds of receiving curative therapy, indicating earlier detection and better candidacy for potentially curative treatment. This reinforces guideline-recommended screening in at-risk populations; the finding that 72% of non-surveillance HCC cases had HBV and 54% had cirrhosis underscores real-world surveillance gaps despite guideline consensus.
What it foundHCC surveillance independently predicted curative therapy receipt (OR 17.78, 95% CI 5.56-56.88); in HBV carriers the effect was stronger (OR 26.79) and higher BMI also predicted curative receipt (OR 1.18 per unit). Surveillance-diagnosed patients presented with smaller tumors, lower rates of multifocal disease, and less vascular invasion.
ContextThis literature reports that hepatocellular carcinoma surveillance is associated with differences in tumor features and receipt of curative therapy in patients with chronic hepatitis B and MASLD.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026

Decision at stakewhether and how to implement HCC surveillance in chronic hepatitis B patients, particularly those with cirrhosis

… (6) HCC SURVEILLANCE (all CONDITIONAL, VERY LOW certainty; modality/interval per AASLD 2023 HCC Practice Guidance), Rec 6: after HBsAg loss, continue surveillance in those with cirrhosis, family history of HCC, men who lost HBsAg after age 40, and women who lost HBsAg after age 50. … Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

The 2026 AASLD/IDSA guideline addresses six PICO questions only; it states explicitly that all other 2018 AASLD recommendations for CHB management remain applicable, and that screening/diagnosis were out of scope. Baseline evaluation and the standard treatment indications (cirrhosis with detectable HBV DNA; HBeAg-positive immune-active with ALT >2x ULN and HBV DNA >20,000 IU/mL; HBeAg-negative immune-active with ALT >2x ULN and HBV DNA >2,000 IU/mL; prophylaxis for reactivation risk during immunosuppression) derive from the 2018 document, not this update, which lists 'treatment of HBeAg-positive and -negative immune active CHB with ALT >2x ULN', treatment of children, treatment of cirrhosis, low-level viremia, virologic breakthrough, and special populations (transplant, acute HBV, HCV/HDV/HIV coinfection) as topics 'well covered in previous AASLD 2018 Guidance and for which recommendations have not changed'. Preferred agents remain entecavir, TDF, or TAF. THE SIX 2026 RECOMMENDATIONS: (1) PMTCT, for pregnant persons with HBV DNA >200,000 IU/mL at any time point during pregnancy, regardless of HBeAg status, AASLD RECOMMENDS initiating TDF or TAF at gestational week 28 (STRONG recommendation, MODERATE certainty, the only strong recommendation in the guideline); TDF has a more extensive safety record in pregnancy than TAF. Implementation qualifiers: initiate immediately if care is first sought after week 28; initiate at week 16 if infant HBIG will be unavailable (with subsequent infant vaccination); consider earlier initiation when amniocentesis is anticipated (transmission risk is increased with HBV DNA >2,000,000 IU/mL) or when preterm labor risk is high; continue TDF/TAF if already on it, switch entecavir or other agents to TDF/TAF; if treatment was solely for perinatal prophylaxis it may be discontinued at delivery, with HBV DNA and ALT monitored every 1-3 months for up to 6 months for withdrawal flare and treatment reinitiated if ALT >=5x ULN; use TDF or TAF in breastfeeding persons requiring treatment. (2) HORIZONTAL TRANSMISSION, for HBsAg-positive viremic persons not meeting disease-specific treatment indications who are in high-risk scenarios for transmission to others, AASLD SUGGESTS a shared decision-making approach regarding antiviral treatment (CONDITIONAL, VERY LOW certainty). Qualifiers the guideline stresses: the decision weighs exposure risk and the vaccine/immunity status of contacts, favoring treatment if contacts are unvaccinated, vaccine-nonresponsive, immunocompromised, or of unknown vaccine status; persons requesting treatment for prevention may be prescribed it since risks may not be disclosed; explicitly, people with CHB must NOT be restricted in daily activities, contact sports, school, or professional training and must NOT be required to take antivirals because of transmission risk in those settings; routine contact, shared meals, and hugging are not transmission routes (avoid sharing toothbrushes/razors); most healthcare workers with CHB are NOT high-risk, but those performing SHEA Category III exposure-prone procedures may require antivirals (SHEA target HBV DNA <1000 IU/mL); neither CDC nor SHEA requires disclosure to patients or staff; anti-stigma framing is part of the recommendation. (3) IMMUNE-TOLERANT PHASE, defined as HBeAg-positive, HBV DNA >10^7 IU/mL, and normal ALT; AASLD SUGGESTS antiviral therapy for those over age 40 years, OR with significant liver inflammation (grade >=2) or fibrosis (>=F2) on biopsy or noninvasive tests (CONDITIONAL, VERY LOW certainty). For persons under age 40 who are interested in starting treatment earlier, AASLD suggests shared decision-making weighing risk factors and the benefits and risks of treatment. Accurate phase identification requires persistently normal ALT on >=2 measurements >=6 months apart, using ULN 35 U/L (males) and 25 U/L (females). (4) INDETERMINATE ('grey zone') PHASE, the HBeAg-negative indeterminate phase is defined as HBsAg-positive, HBeAg-negative persons whose ALT and/or HBV DNA fall outside the thresholds for HBeAg-negative immune-active CHB (ALT >2x ULN and HBV DNA >2,000 IU/mL) and outside those for inactive CHB (HBV DNA <2,000 IU/mL with normal ALT), comprising predominantly two subgroups, (I) normal (<ULN) or mildly elevated (<2x ULN) ALT with HBV DNA >=2,000 IU/mL, or (II) elevated ALT (>ULN) with HBV DNA <2,000 IU/mL, with ALT interpreted against ULN 35 U/L (males) and 25 U/L (females) and phase assigned on >=2 ALT and HBV DNA measurements over a 6-12 month period; in adults who are HBsAg-positive, HBeAg-negative, without cirrhosis and in the indeterminate phase so defined, AASLD SUGGESTS antiviral therapy using a shared decision-making approach assessing risks and benefits, and re-evaluating that decision at each follow-up visit if treatment has not been initiated (CONDITIONAL, VERY LOW certainty). Decision-relevant factors include fibrosis stage, age, and sex, e.g. age >40, male sex, and low-normal platelets (<180 k/mm3) favor treatment. (5) DISCONTINUATION, in adults with CHB who are HBeAg-negative, without cirrhosis, with sustained undetectable HBV DNA on nucleos(t)ide analogue therapy, AASLD SUGGESTS NOT withdrawing NA therapy until HBsAg loss (CONDITIONAL, VERY LOW certainty). If a patient nonetheless has a strong desire to stop, shared decision-making applies and ALL of the following must be met: no history of advanced fibrosis/cirrhosis, hepatic decompensation (variceal bleed, ascites, encephalopathy, hepatorenal syndrome), HCC, or extrahepatic HBV complications; if HBeAg-positive at treatment start, HBeAg seroconversion to anti-HBe-positive for >=1 year with undetectable HBV DNA >=2 years; if HBeAg-negative at start, undetectable HBV DNA >=2 years; no HIV or HDV coinfection; quantitative HBsAg <100 IU/mL; and willingness to adhere to frequent monitoring. After stopping, monitor ALT and HBV DNA every 1-3 months for 6 months, then every 3 months for 6-12 months, then every 3-6 months. Restart antivirals IMMEDIATELY if HBV DNA >=10,000 IU/mL (4 log IU/mL) at any time regardless of ALT, OR ALT >=5x ULN regardless of HBV DNA, OR total bilirubin >2.5 mg/dL. (6) HCC SURVEILLANCE (all CONDITIONAL, VERY LOW certainty; modality/interval per AASLD 2023 HCC Practice Guidance), Rec 6: after HBsAg loss, continue surveillance in those with cirrhosis, family history of HCC, men who lost HBsAg after age 40, and women who lost HBsAg after age 50. Rec 7: in HBV-HDV coinfection, surveil adults independent of cirrhosis status; in children, individualize because HCC risk in that population is unknown. Rec 8: in HBV-HIV coinfection, surveil men >=18 years and women >=40 years. Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria. Where a person has more than one coinfection, the surveillance recommendation should follow the coinfection carrying the highest associated risk. The guideline notes that most of its recommendations rest on low or very low certainty evidence and that shared decision-making, not uniform policy, is the intended mode of application.

American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026 · reviewed 2026-07-23 ↗
Huang SL … Kao JH · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
Hepatology prospective cohort · n=138,996 · Sep 7, 2026 · Aliment Pharm Ther · IF 6.7

Long-Term Major Adverse Liver Outcomes and Oncological Outcomes Across Steatotic Liver Disease Subtypes Classified Using the MetALD-ALD Prediction Index.

Epidemiologyhepatocellular carcinomaMASLDalcohol-associated liver diseaseepidemiology
Clinical takeawayIn UK Biobank participants free of cancer at baseline, ALD was associated with 1.70-fold higher MALO risk and 3.07-fold higher HCC risk compared with MASLD. MAPI specifics and classification thresholds live in the source. Alcohol underreporting may cause misclassification between MetALD and ALD. Prospective clinical utility and practical implementation for routine surveillance and referral decisions remain unvalidated.
What it foundAmong 138,996 SLD patients, ALD conferred 1.70-fold higher risk of major adverse liver outcomes and 3.07-fold higher hepatocellular carcinoma risk compared with MASLD; MetALD showed intermediate risks for cancer but not MALO.
ContextRetrospective risk stratification in a UK biobank cohort. Demonstrates distinct outcome risks by SLD subtype but does not establish prospective validity of MAPI as a practical classification tool for clinic-based use.
Reinforcessuggested applicable standard· American College of Gastroenterology (ACG), "ACG Clinical Guideline: Alcohol-Associated Liver Disease" (Jophlin, Singal, Bataller, et al.), Am J Gastroenterol 2024;119(1):30-54

Decision at stakeWhether hepatocellular carcinoma surveillance should be intensified in alcohol-associated liver disease

… For alcohol-associated hepatitis (AH), severity is stratified by MELD: MELD >20 defines severe AH, which carries high short-term mortality and should preferably be managed in hospital; MELD ≤20 defines moderate AH. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Treatment of AUD with sustained abstinence is the most effective strategy to prevent progression and improve long-term outcomes at any stage of ALD; ACG recommends brief screening with a tool such as AUDIT-C (strong, high), brief motivational interventions (strong, low), and integrated multidisciplinary care combining behavioral therapy and/or pharmacotherapy (strong, low). AUD pharmacotherapy recommendations are scoped specifically to COMPENSATED ALD and are not co-equal: baclofen is recommended as an option (strong recommendation, moderate evidence); acamprosate or naltrexone are only suggested as options (conditional, very low); gabapentin or topiramate are suggested as options (conditional, very low); disulfiram is suggested AGAINST along any spectrum of ALD (conditional, very low). For severe alcohol withdrawal, benzodiazepines are the treatment of choice but with explicitly cautious use and careful monitoring given their potential to precipitate or exacerbate hepatic encephalopathy (strong, moderate); AWS is managed per CIWA-Ar protocol, differentiating it from HE while acknowledging the two can coexist. For alcohol-associated hepatitis (AH), severity is stratified by MELD: MELD >20 defines severe AH, which carries high short-term mortality and should preferably be managed in hospital; MELD ≤20 defines moderate AH. In severe AH (MELD >20) ACG recommends corticosteroid therapy ONLY if there are no contraindications (strong, moderate); active infection (including untreated HBV infection), uncontrolled diabetes mellitus, gastrointestinal bleeding, and severe renal failure are contraindications to corticosteroid use, though corticosteroids can be started after adequate control or reversal of infection, renal failure, and gastrointestinal bleeding. Prednisolone is preferred over prednisone; both are dosed 40 mg/day for a total of 4 weeks, with IV methylprednisolone 32 mg/day as the alternative for patients unable to take oral medication; there is no evidence supporting rapid vs slow tapering after the 4-week course. Corticosteroid response is assessed by Lille score at day 7 OR day 4 (day-4 shown as accurate as day-7); among non-responders (Lille >0.45) corticosteroids should be discontinued. ACG recommends IV N-acetylcysteine as an adjuvant to corticosteroids in severe AH (strong, moderate), while explicitly noting that other society guidelines have not adopted this recommendation. ACG recommends AGAINST pentoxifylline (strong, moderate) and AGAINST universal prophylactic antibiotics in hospitalized severe AH (strong, moderate); data on G-CSF and microbiome-based therapies are insufficient. Nutrition: target 35 kcal/kg/day with 1.2-1.5 g/kg/day protein; patients consuming <21 kcal/kg/day should receive nutritional support, preferably oral/enteral, oral nutritional supplements first, escalating to enteral nutrition if caloric targets remain unmet (strong, moderate). Thiamine, vitamin B12 and zinc deficiencies are common in AH and should be supplemented. For severe AH unresponsive to medical management with high risk of death, early liver transplantation for highly selected patients should be considered according to regional and institutional protocols (conditional recommendation, low level of evidence); LT selection must not be based solely on an arbitrary duration of sobriety, and should rest on detailed psychosocial evaluation by a social worker and addiction specialist, optionally supported by tools such as SIPAT, HRAR, MAPS, HPSS or SALT. For severe AH with 4 or more organ failures, non-responsive to corticosteroids and ineligible for early LT, palliative care engagement is appropriate.

American College of Gastroenterology (ACG), "ACG Clinical Guideline: Alcohol-Associated Liver Disease" (Jophlin, Singal, Bataller, et al.), Am J Gastroenterol 2024;119(1):30-54 · reviewed 2026-07-20 ↗
Li Y … Wu S · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink

Endoscopy· 1

Endoscopy guideline · Sep 9, 2026 · Clin Gastro Hep · IF 16.2

AGA Clinical Practice Update on Management of Ampullary Neoplasms: Expert Review.

Guideline / reviewguideline
Clinical takeawayFor patients with suspected ampullary adenoma, use a side-viewing duodenoscope (not forward-viewing gastroscope) with careful biopsy technique-avoiding the pancreatic orifice to minimize pancreatitis risk-and obtain at least 6 biopsies, prioritizing ulcerated or indurated areas, to assess for occult malignancy. Perform EUS staging in adenomas considered for endoscopic resection, except lesions <1 cm with no worrisome features.
What it found20%-40% of ampullary adenomas harbor malignancy; AGA recommends side-viewing duodenoscope assessment with at least 6 biopsies from ulcerated or indurated areas, and EUS staging for adenomas amenable to endoscopic resection.
ContextAmpullary neoplasia is rare (0.6%-0.8% of GI cancers) with 5-year survival ranging 20%-75% by stage. This AGA expert review fills a documented gap in formalized guidance and standardizes assessment technique, particularly relevant given rising incidence in young adults.
Measured against the standard of care· AGA Clinical Practice Update (Expert Review) 2026 / ESGE 2021

Decision at stakedetermine which ampullary adenomas are candidates for endoscopic versus surgical management

… SELECTION: AGA describes the lesion most amenable to papillectomy as having well-defined margins, size <4-5 cm, nonfriable tissue, softness to probing, and intraductal extension <=1 cm. AGA sets 3 absolute contraindications: metastatic spread; invasive cancer beyond the mucosa; and >1 cm intraductal extension in a surgically fit patient. … For >1 cm intraductal extension, AGA suggests surgical consultation; <1 cm may be treated endoscopically with close surveillance. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS, STAGING, TECHNIQUE and 5 more.

Our full summary of this standard

Two current documents govern ampullary adenoma: the AGA Clinical Practice Update expert review (Barakat, Maranki, Irani, Chahal; Clin Gastroenterol Hepatol, online 2026-09-09; ungraded Best Practice Advice from literature review plus expert opinion, no systematic review) and the ESGE 2021 graded guideline (Vanbiervliet et al., Endoscopy 2021;53:429-448), which it does not replace. DIAGNOSIS: both use a side-viewing duodenoscope. AGA adds that biopsies should avoid the pancreatic orifice to limit post-procedure pancreatitis. Because 20-40% of ampullary adenomas harbor malignancy, AGA advises AT LEAST 6 biopsies, targeting ulcerated or indurated areas. ESGE requires proven adenoma before papillectomy and recommends against diagnostic papillectomy. STAGING: AGA says to consider EUS for every adenoma potentially amenable to endoscopic resection, EXCEPT lesions <1 cm with no worrisome clinical or endoscopic features. ESGE recommends EUS plus MRCP (IDUS in selected patients) and advises against routine molecular testing of biopsies. SELECTION: AGA describes the lesion most amenable to papillectomy as having well-defined margins, size <4-5 cm, nonfriable tissue, softness to probing, and intraductal extension <=1 cm. AGA sets 3 absolute contraindications: metastatic spread; invasive cancer beyond the mucosa; and >1 cm intraductal extension in a surgically fit patient. Relative contraindications are size >5 cm, early-stage/T1 cancer, and likely poor follow-up adherence. For >1 cm intraductal extension, AGA suggests surgical consultation; <1 cm may be treated endoscopically with close surveillance. This is a stricter intraductal threshold than ESGE's, which suggests surgery only for intraductal involvement >20 mm and adjunct RFA or cystotome ablation with temporary biliary stenting for <=20 mm in expert centers. ESGE also gates en bloc resection at adenomas up to 20-30 mm and lists >4 cm or a periampullary diverticulum as technical reasons to consider surgery. TECHNIQUE: both say to avoid biliary or pancreatic sphincterotomy before papillectomy (AGA's reasons: cautery artifact and bleeding) and to use en bloc snare resection when feasible. Submucosal injection is generally not needed, except for a laterally spreading duodenal-wall component. ESGE also suggests endocut current. PANCREATITIS PROPHYLAXIS: AGA advises using ALL THREE together: prophylactic pancreatic duct stent, rectal NSAID, and high-volume lactated Ringer's. ESGE recommends the PD stent and rectal diclofenac or indomethacin 100 mg, with lactated Ringer's suggested mainly when stenting is not possible. BLEEDING: standard hemostasis methods (epinephrine, electrocoagulation, clips, APC, hemostatic sprays); ESGE says prophylactic hemostasis is individualized. BILIARY DRAINAGE when resection is not feasible: AGA allows drainage with or without sphincterotomy and SEMS for significant jaundice or cholangitis, at the surgeon's discretion. ESGE recommends against routine preoperative drainage, reserving it for cholangitis, severe jaundice, delayed surgery, or neoadjuvant therapy, with SEMS when drainage is needed. ADJUNCT/RESIDUAL: for adenomas >3 cm resected piecemeal or with positive margins, AGA advises considering adjunct thermal ablation plus ductography, repeated every 2-3 months until biopsy confirms eradication. ESGE allows APC and EMR for benign residual or recurrent lesions. SURVEILLANCE: both use the same schedule: side-viewing duodenoscopy with biopsy of the scar and any abnormal area at 3 months, then at 6 and 12 months, then yearly for at least 5 years. AGA says surveillance beyond 5 years should be individualized (recurrence risk, comorbidity, life expectancy) but is required if high-risk features are present. In FAP, AGA individualizes intervals by ampullary, gastric and duodenal disease burden. MALIGNANCY: AGA advises multidisciplinary discussion (GI, surgery, oncology) for high-grade dysplasia, incomplete resection, or suspected malignancy. ESGE recommends pancreaticoduodenectomy with lymphadenectomy for T1 or higher, and accepts local resection for Tis when final pathology shows no residual disease.

AGA Clinical Practice Update (Expert Review) 2026 / ESGE 2021 · reviewed 2026-10-11 ↗
Barakat M … Chahal P · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink

Colorectal· 1

Colorectal guideline · Sep 7, 2026 · Gut · IF 24.6

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement.

Guideline / reviewMASLDcolorectal cancercolorectal cancer screeningguideline
Clinical takeawayHeighten CRC surveillance in MASLD patients; screening intensity should be informed by MASLD severity (worse outcomes with advanced disease), though specific severity-based intervals are not defined in this consensus. Coordinate with hepatology for risk-adapted screening strategy. Include metabolic management (weight loss, GLP-1 agonists where indicated, bariatric surgery where eligible); no proven CRC risk-reduction benefit from these interventions in MASLD is presented.
What it foundDelphi consensus: MASLD associates with increased CRC risk; severity of MASLD is associated with worse CRC outcomes, and metabolic burden further increases risk. Risk stratification by MASLD severity grade is not specified in this consensus. Quantitative risk elevation not specified.
ContextConfirms epidemiological association between MASLD and elevated CRC risk. Severity of MASLD is associated with worse CRC outcomes, suggesting it should inform surveillance strategy, but severity-based risk categories for screening are not defined. Expert agreement on gut-liver axis and dysbiosis provides mechanistic plausibility without clinical thresholds. Current practice applies standard CRC risk stratification without MASLD-specific adjustment.
Measured against the standard of care· AASLD 2023 Practice Guidance (with October 2024 resmetirom and November 2025 semaglutide updates) / EASL 2026 holistic guidance on the steatotic liver disease trajectory (JHEP Reports 2026;8(9):101798)

Decision at stakeCRC screening strategy and intensity for patients with MASLD

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Lifestyle change is still the foundation of MASLD care, and it is graded by goal. For adults with overweight or obesity, sustained loss of ≥5% of body weight reduces liver fat, 7-10% improves steatohepatitis, and ≥10% improves fibrosis. In lean MASLD the target is 3-5% loss. Diet should follow a Mediterranean pattern. Sugar-sweetened beverages are restricted first; fructose and other sugars, refined carbohydrates, saturated fat, ultra-processed food and red or processed meat are also cut. Low-carbohydrate diets or time-restricted eating are acceptable if they keep Mediterranean principles. Patients should do ≥150 min/week of moderate aerobic exercise plus resistance training (resistance work protects against sarcopenia and suits patients who cannot do aerobic exercise) and should cut sedentary time. Any amount of alcohol is treated as potentially hazardous: screen with AUDIT-C, and in compensated advanced chronic liver disease (cACLD) or cirrhosis advise abstinence. Drugs and surgery are added to lifestyle, never substituted for it, and each is limited by disease stage. Resmetirom is approved by the FDA and EMA (EMA in May 2025), with diet and exercise, for noncirrhotic MASH with F2-F3 fibrosis; it is not for cirrhosis. GLP-1 receptor agonists, or dual GIP/GLP-1 agonists, are the preferred class for patients with type 2 diabetes and/or obesity. Semaglutide 2.4 mg has FDA accelerated approval and AASLD November 2025 guidance support for noncirrhotic MASH F2-F3, with cirrhosis excluded first by noninvasive tests. Anti-obesity drugs are not yet recommended in cirrhosis. Pioglitazone is for selected patients, with or without diabetes, with biopsy-proven MASH (AASLD); it is not for all patients with MASLD and should be avoided in cACLD or cirrhosis. Under AASLD 2023, vitamin E 800 IU/day is limited to biopsy-proven MASH without diabetes or cirrhosis; the 2026 EASL guidance does not cover it. Bariatric or metabolic surgery should be discussed at BMI >35 kg/m2 with comorbidity, or ≥40. In compensated cirrhosis it may help carefully selected patients (MELD <12, Child-Pugh A), usually by sleeve gastrectomy, done at high-volume centres if clinically significant portal hypertension (CSPH) is present. It is contraindicated in decompensated cirrhosis. Comorbidity care is part of MASLD treatment: cardiovascular risk, under-prescribed statins (safe in compensated cirrhosis; avoid high doses when decompensated), diabetes, sleep apnea, mental health and sleep, and vaccination.

AASLD 2023 Practice Guidance (with October 2024 resmetirom and November 2025 semaglutide updates) / EASL 2026 holistic guidance on the steatotic liver disease trajectory (JHEP Reports 2026;8(9):101798) · reviewed 2026-10-11 ↗
Wu CT … Zheng MH · Gut · IF 24.6 · PubMed ↗Permalink

Nutrition· 1

Nutrition retrospective · n=5,174,261 · Sep 9, 2026 · Am J Clin Nutrition · IF 6.5

Acute Hyperglycemia During Hospitalization, Nutritional Support, and Longer-Term Cardiovascular Outcomes: a Nationwide Real-World Data Cohort Study.

New evidenceenteral nutritionparenteral nutritionepidemiology
Clinical takeawayIn non-diabetic adults without baseline cardiovascular disease, risk-stratify post-discharge patients based on acute hospitalization hyperglycemia. Counsel patients with glucose >180 mg/dL during admission about elevated long-term cardiovascular risk and consider intensified cardiovascular risk factor management (BP control, lipid management, smoking cessation, weight/glucose targets). Effect is more pronounced in patients who received parenteral or enteral nutrition. This observational study identifies an association but does not establish causality or demonstrate that acute glucose control itself reduces subsequent cardiovascular outcomes.
What it foundAcute hyperglycemia (blood glucose >180 mg/dL) during hospitalization, present in 26.8% of non-diabetic patients, associated with a 1.82-fold increased risk of composite cardiovascular events over median 2.3 years post-discharge (95% CI 1.80-1.84); risk rose to 2.11-fold with parenteral nutrition and 1.95-fold with enteral nutrition.
ContextPrior evidence established acute hyperglycemia as a marker of acute illness severity; this extends that finding to show persistent long-term cardiovascular consequences in non-diabetic patients years after discharge. Novel is the interaction with nutritional support-effect strongest with parenteral nutrition (2.11-fold), intermediate with enteral (1.95-fold), and weaker without nutritional support (1.35-fold)-suggesting nutritional route or severity of illness modifies the association. The mechanism remains unexplained; unmeasured confounding (unmeasured illness severity, complications, or metabolic derangement) cannot be ruled out.
Emergingsuggested applicable standard· American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149

Decision at stakemanaging acute hyperglycemia in non-diabetic hospitalized patients receiving nutritional support

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Manage diabetes in GI/hepatology patients by individualizing the A1c target to the population, in cirrhosis, A1c is unreliable because altered red blood cell turnover typically underestimates glycemia, so set glycemic goals using blood glucose monitoring and/or CGM rather than a fixed A1c cutoff, and in diabetic gastroparesis individualize the target rather than applying a universal cutoff; ≤7% pre-bariatric, <6.5% pre-conception, while screening all T2DM for MASLD with FIB-4, screening T1DM for concurrent celiac disease, and screening for diabetic gastroparesis when chronic nausea, early satiety, or postprandial fullness are present. Evaluate new-onset DM after age 50 without obesity for a pancreatic cancer differential, and coordinate peri-procedural medication holds and multidisciplinary endocrinology involvement.

American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149 · reviewed 2026-07-23 ↗
Santos MP … Ley SH · American Journal of Clinical Nutrition · IF 6.5 · PubMed ↗Permalink
Everything else this week30 that cleared the bar

Ranked below the cards above, not excluded: these met the bar and were read and scored the same way. One line each, grouped by subspecialty, highest signal first; click through for the paper.

Also screened this week49 papers read, not selected

These cleared the journal filter and were read, but were not selected this week. A score means the paper was weighed: below 35 it fell short of the bar; at 35 or above, a check after scoring set it aside. A blank means it was set aside before scoring. Listed for anyone going deeper; no takeaway attached, because none was written. How we choose →

Endoscopy· 24

How we choose

the same pipeline every week
01

Scan

Every new paper across 48 vetted GI, hepatology, and general-medicine journals.

02

Screen

Drop what is not a study: letters, editorials, corrections, case reports. Classify the rest.

03

Anchor

Compare each paper to the guideline standard it touches, and record how far it moves it.

04

Verify

An adversarial second pass checks every claim against its cited source.

05

Vet

Each issue is reviewed by a physician editor before it publishes.